Oculis

35 articles about Oculis

• Oculis to Participate and Present at Upcoming EuDES Meeting

  5/24/2023

  Oculis Holding AG announces that its Head of Development, Dr. Bastian Dehmel, will be participating in the 2023 EuDES (European Dry Eye Society) Meeting in Munich, Germany on June 2-3, 2023.

• Oculis Announces Positive Top Line Results from DIAMOND Stage 1 Phase 3 Trial in Diabetic Macular Edema with OCS-01 Eye Drops

  5/22/2023

  Oculis Holding AG, a global biopharmaceutical company purposefully driven to save sight and improve eye care, announced positive top line results from Stage 1 of its Phase 3 DIAMOND trial of OCS-01 eye drops in Diabetic Macular Edema.

• Oculis Co-founders Selected as Finalists in European Inventor Award 2023

  5/11/2023

  Oculis Holding AG announced the nomination of its co-founders, Professors Einar Stefánsson and Thorsteinn Loftsson, as finalists in the ‘Research’ category of the European Inventor Award 2023.

• Oculis Opens New Offices in the US and Expands its US Team by Appointing Dr. Fang Li as Senior Vice President, Regulatory Affairs

  4/26/2023

  Oculis Holding AG today announced the opening of its Boston, Massachusetts office, expanding its US presence in preparation of becoming an active player in the US market and demonstrating execution of its strategy. This includes the hiring of Dr. Fang Li as the new US-based Senior Vice President, Regulatory Affairs.

• Oculis to Participate at Upcoming April 2023 Investor Conferences

  4/5/2023

  Oculis Holding AG announces that members of management will be participating in the following April investor conferences.

• Oculis to Host Conference Call on April 13, 2023 to Discuss Late-Stage Pipeline and Near-Term Clinical Milestones

  4/4/2023

  Oculis Holding AG announces that it will host a virtual conference call and webcast to present an overview of its late-stage pipeline and discuss expected near-term clinical milestones on Thursday, April 13 from 8:00am-9:00am ET / 13:00-14:00 BST / 14:00-15:00 CET.

• Oculis to Ring Nasdaq Stock Market Opening Bell in Celebration of its Successful Listing

  3/22/2023

  Oculis Holding AG announces that it will ring the Nasdaq opening bell to celebrate its public listing on the Nasdaq Stock Market earlier this month.

• Oculis Completes Enrollment in Phase 3 OCS-01 OPTIMIZE Trial

  3/16/2023

  Oculis Holding AG (Nasdaq: OCS) (“Oculis”) a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announces the completion of enrollment for its Phase 3 OPTIMIZE trial evaluating the efficacy and safety of once-daily OCS-01.

• Oculis Announces US Public Listing on NASDAQ

  3/3/2023

  Oculis Holding AG (“Oculis”) a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announces its listing on Nasdaq after successfully closing the business combination between European Biotech Acquisition Corp. (“EBAC”) and Oculis SA.

• Oculis completes patient recruitment for stage 1 of Phase 3 DIAMOND study evaluating the efficacy and safety of OCS-01 in diabetic macular edema (DME)

  1/5/2023

  Oculis S.A. announces the completion of enrollment for stage 1 of its Phase 3 DIAMOND study evaluating the efficacy and safety of OCS-01 in patients with diabetic macular edema.

• Oculis Strengthens its Scientific Advisory Board with World-Leading Ophthalmology Experts to Support Pipeline Development

  11/3/2022

  Oculis S.A. announced significant expansion of its Scientific Advisory Board with the appointments of six world-leading medical experts, Christophe Baudouin, M.D., PeterK.

• Oculis SA and European Biotech Acquisition Corp announce business combination agreement to create Nasdaq-listed biopharmaceutical company driving breakthrough innovations in ophthalmology

  10/17/2022

  Oculis, SA. (“Oculis”), a global biopharmaceutical company developing treatments to save sight and improve eye care with breakthrough innovations and European Biotech Acquisition Corp (“EBAC”, NASDAQ: EBAC), a special purpose acquisition company (SPAC), today announced they have entered into a definitive business combination agreement.

• Oculis announces publication and presentation of Phase 2 data showing topical OCS-01 improves macular thickness and visual acuity in patients with diabetic macular edema

  9/6/2022

  Oculis S.A. announces that the Phase 2 DX-211, a randomized, double blinded, multi-center and vehicle controlled clinical trial assessing the safety and efficacy of topical OCS-01 in patients with Diabetic Macular Edema has been published by the Acta Ophthalmologica journal.

• Oculis announces publication of Phase 2 data showing topical eye drops anti-TNFα agent licaminlimab (OCS-02) relieves persistent ocular discomfort in severe dry eye disease

  8/23/2022

  Oculis S.A. announces that the results of the double blinded, multicenter and placebo controlled Phase 2 clinical trial assessing the effect of topical licaminlimab on global ocular discomfort in patients with severe dry eye disease has been published by the Clinical Ophthalmology journal.

• Oculis Announces First Patient Enrolled in Phase 3 OPTIMIZE Trial of OCS-01 in the Treatment of Inflammation and Pain Following Cataract Surgery

  6/29/2022

  Oculis S.A. announced that the first patient has been enrolled in its Phase 3 OPTIMIZE trial evaluating the efficacy and safety of once-daily OCS-01, a novel, high concentration, preservative-free, topical OPTIREACH formulation of dexamethasone for the treatment of inflammation and pain following cataract surgery.

• 

  2023 Will Be Pivotal Year for Oculis’ Potentially Transformative Medicines

  4/4/2022

  Oculis has identified pressing unmet therapeutic needs and innovative, differentiated approaches to meet those needs.

• Oculis appoints Dr. Bastian Dehmel as Chief Development Officer

  2/8/2022

  Oculis S.A. announces the further strengthening of the Company’s executive leadership team with the appointment of Dr. Bastian Dehmel as global Chief Development Officer.

• Oculis appoints Mr. Webb Ding as Global Chief Operating Officer and General Manager (China)

  1/5/2022

  Oculis S.A. announces the appointment of Mr. Webb Ding as global Chief Operating Officer and General Manager, China, with effect from February 1, 2022.

• Oculis Announces Positive Data from Two Proof-of-Concept Phase 2 Trials with OCS-02, a Novel Topical TNF alpha Antagonist, in Dry Eye Disease and Acute Anterior Uveitis, Presented at ARVO 2021

  5/11/2021

  Positive Phase 2a data, presented for the first time, highlights the potential of OCS-02 to become a new treatment in moderate to severe DED and potentially the first personalized therapy in this disease.

• Oculis Announces an Oversubscribed US$57 million Series C Financing

  5/4/2021

  Advance novel, late-stage Investigationalophthalmology drugs OCS-01 and OCS-02 and deliver the first topical drug for retinal edema.